Antiphospholipid antibody production in pregnant women with SARS-CoV-2 infection and its impact on maternal and fetal outcomes

作者：Shenglong Ye, Yilin Wang, Jingjing Yang, Yang Zhang, Zhe Chen, Ran Hu, C Li, Xue Xu, Meiying Liang · 发表于：Frontiers in Immunology · 年份：2026 · DOI：10.3389/fimmu.2026.1810392 · 研究领域：COVID-19 Impact on Reproduction、Systemic Lupus Erythematosus Research、COVID-19 Clinical Research Studies

Objective To investigate the prevalence of antiphospholipid antibodies (aPLs) in pregnant women infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their impact on maternal-fetal outcomes, with an emphasis on gestational stage-specific differences and lupus anticoagulant (LAC) positivity. Methods This prospective, observational cohort study was conducted at the Department of Obstetrics, Peking University People’s Hospital, from December 2022 to January 2023. Eligible participants were singleton pregnant women without pre-existing pregnancy complications who tested positive for SARS-CoV-2. Serum samples were collected 2–4 weeks post-infection for testing of aPLs, including LAC, anti-β2-glycoprotein I (aβ2GPI), and anticardiolipin antibodies. Maternal and fetal outcomes were monitored according to standard prenatal care protocols, with specific attention to placental dysfunction related complications. Results The overall prevalence of aPLs in pregnant women infected with SARS-CoV-2 was 18.75%. All positive cases were single-antibody positive, either for aβ2GPI or LAC, with no instances of multiple antibody co-positivity. The prevalence of aPLs was significantly correlated with the gestational stage at the time of infection, rising from 5.88% in the first trimester to 16.00% in the second trimester and 26.31% in the third trimester ( P<0.05 ). Notably, all LAC-positive cases (constituting 8.25% of total infections) were exclusive to women infect...